Table 1.
Clinical characteristic of patients with POLE-mutant endometrioid endometrial adenocarcinomas.
| Clinical characteristics |
POLE-mutant EECs (n=23) n (%) |
|---|---|
| Age at diagnosis; years (range) | 54 (43–76) |
| Stage at diagnosis | |
| I | 19 (83) |
| II | 0 (0) |
| III | 2 (9) |
| IV | 2 (9) |
| Histologic grade | |
| 1 | 6 (26) |
| 2 | 7 (30) |
| 3 | 10 (44) |
| Adjuvant therapy | |
| No adjuvant treatment | 6 (26) |
| Radiation | 9 (39) |
| Chemotherapy | 2 (9) |
| Radiation and chemotherapy | 5 (22) |
| Hormonal treatment | 1 (4) |
| Metastatic disease | |
| De novo stage IV | 2 (9) |
| Recurred | 4 (17) |
| Progression of disease after initial treatment | 1 (4) |
| Did not recur | 17 (74) |
| Status at last follow up | |
| No evidence of disease | 20 (87) |
| Alive with disease | 2 (9) |
| Deceased | 1(4) |
EEC, endometrioid endometrial cancer